C oronary occlusion during the acute stage of myocardial infarction results from a complex interaction of factors including plaque fissure,1 platelet deposition,2 arterial spasm,3 and fibrin deposition.4'5 Spontaneous recanalization, which has also been documented, may result from resolution of spasm,3 breakdown of platelet deposits,2 and activation of the endogenous thrombolytic system. 6 The balance of these processes can be shifted toward recanalization by administration of thrombolytic agents but not spasmolytic agents such as nitroglycerin. 6 Changes of antegrade flow result in altered pressure gradients across collateral beds7 and variations in collateral flow. 8 In the present study, we assessed occlusion status of the infarct artery and collateral flow to the infarct region by serial angiography in patients treated with an intracoronary infusion of streptokinase, nitroglycerin, or both agents within 12 hours of onset of infarction. We, therefore, were able to compare these angiographic parameters prospectively in patients who received a thrombolytic agent and in those who did not. Additionally, we evaluated the time dependence of infarct vessel patency and collateral flow at baseline angiography, as well as the time dependence of intracoronary streptokinase in achieving recanalization. Finally, we assessed the complications of interventional angiography in acute myocardial infarction.
The angiographic and clinical results presented in this study are secondary end points in the Second Mt. Sinai-New York University Reperfusion Trial, in which ejection fraction change was the primary end point. As reported previously, the greatest improvement in ejection fraction occurred in patients with collateralized total occlusion at preintervention angiography who were assigned to thrombolytic therapy; this benefit was potentiated by the concomitant administration of nitroglycerin.9 In patients with initial subtotal occlusion, thrombolytic therapy was found to be of no short-term benefit.
Methods

Trial Design
The trial design has been published.9 Consenting patients in whom thrombolytic therapy was not contraindicated6 were eligible if they presented within 12 hours of the onset of myocardial ischemic pain of at least 30 minutes duration and demonstrated either new ST segment elevations or depressions of at least 0.1 mV, or presumably new pathologic Q waves in two contiguous leads of the screening electrocardiogram. Patients were prospectively stratified according to duration of pain before randomization into two groups: group A, patients having pain for less than 2 hours; group B, patients having pain for 2-12 hours. Patients were randomly assigned to one of three intervention arms or a control arm. In the intervention arms, acute cardiac catheterization was followed by a double-blind intracoronary infusion of either streptokinase (SK arm), nitroglycerin (NTG arm), or streptokinase combined with nitroglycerin (SK-NTG arm). In the control arm, acute cardiac catheterization and intracoronary drug infusions were not performed. On day 10-14, end-point coronary angiography and left ventriculography were performed in all consenting patients including those of the control arm. Thus, serial angiograms were obtained in the three intervention arms, whereas in the control arm only an endpoint angiogram was performed.
The angiographic end points were: patency status of the infarct related artery before intervention and 10-14 days later, acute and delayed recanalization rates, reocclusion rates, and presence or absence of collateral flow to the infarct area before intervention and 10-14 days later. Infarct-vessel patency and collateral flow at baseline angiography, as well as recanalization rates with streptokinase, were assessed as a function of the time interval from onset of infarct pain to interventional angiography. The clinical end points were mortality, cardiac arrest, ventricular arrhythmias requiring electrical conversion, cardiogenic shock, reduction of hematocrit to less than 30%, need for blood transfusions, reduction of fibrinogen levels after interventional therapy, reinfarction rates, and the incidence of special procedures including intra-aortic balloon counterpulsation, percutaneous transluminal coronary angioplasty, and coronary artery bypass surgery.
Randomization and Interventional Catheterization
Randomization was carried out by opening a consecutively numbered sealed opaque packet that contained two vials. In the intervention patients, one vial contained a powder, either 250,000 units streptokinase or a placebo; the other vial contained a liquid, either 1.2 mg nitroglycerin or 5% dextrose in water. There was an equal probability that the powder, the liquid, or both were active. In the 25% of patients randomized to the control arm, both vials contained a blue liquid; there was a set of instructions stating "Medical Therapy-No Acute Intervention."
In those patients randomized to interventional therapy, coronary angiography was performed after preintervention nuclear studies. The noninfarct vessel was visualized first. Contrast cineventriculography was not performed as part of the interventional angiogram. During intracoronary drug infusion, the infarct-related artery was visualized in a fixed projection every 15 minutes.
The powder and liquid were reconstituted and added to a 1-1 bottle of 5% dextrose and water and infused into the ostium of the infarct-related artery at a rate of 8 
Concomitant Therapy
Immediately after arterial access in intervention patients and baseline evaluation in control patients, a bolus of 10,000 units heparin was administered and anticoagulation was maintained with heparin followed by warfarin for 3 months. Additional details of concomitant and follow-up medical therapy have been described.6 Acute intra-aortic balloon counterpulsation was used not only in patients who showed clinical signs of cardiogenic shock, as in our first trial but also in clinically stable patients if the preintervention gated blood-pool scan revealed an ejection fraction of less than 30% and either the cardiac index was less than 1.8 1/min/m2 or the pulmonary wedge pressure was more than 25 mm Hg. Whenever possible, neither coronary angioplasty nor bypass surgery were performed before end-point data acquisition.
Data Evaluation
The core laboratory interpreted the angiograms of each intervention patient sequentially from preintervention to end-point study. Subsequently, the end-point angiograms of all patients were read without knowledge of the acute angiographic findings or whether the patient had been treated conventionally. Location and severity of coronary artery lesions were recorded according to the CASS criteria.10 The infarct-related artery was identified in the data center by clinical investigators on the basis of the composite angiographic, electrocardiographic, and nuclear data. The infarct-related artery was classified as "totally obstructed" if there was complete cessation of antegrade flow; it was called "patent" if there was any antegrade flow beyond the culprit lesion. Collateral vessels were determined to be present if any segment of the infarct-related artery filled in any other than a continuous antegrade manner.
Complications and special procedures were assessed in two categories, those occurring during or directly related to intervention and those occurring in hospital through day 14. The incidence of a composite adverse outcome, defined as either death, cardiac arrest, cardiogenic shock, or ventricular arrhythmia requiring electrical conversion, was assessed during intervention and in the control group during a corresponding 90-minute observation period after baseline data acquisition. Mortality was determined at 24 hours after randomization, at hospital discharge, and after 2 years. Fibrinogen was determined by the heat precipitation method'1 before and immediately after interventional catheterization and, in control patients, before and after the 90-minute observation period.
Statistical Analysis
This trial was analyzed by intention to treat. The influence of time was assessed according to the prospective stratification by comparing the variables in groups A and B. In the intervention arms, time to catheterization was also considered. Continuous variables are expressed as mean± SD, except where SEM was used. Differences in the distribution of baseline variables among the four treatment arms were compared using analysis of variance for continuous variables and x2 analysis for categoric variables. Likelihood ratio, x2, and Fisher's exact test were used to analyze all categoric variables.
Results
Patient Profile
The study population consisted of 393 patients; 97 were randomly assigned to the SK arm, 99 to the NTG arm, 96 to the SK-NTG arm, and 101 to the control arm; 78 patients were enrolled in group A and 315 were enrolled in group B. Time from onset of pain to interventional catheterization was 3.2+ 0.7 hours in group A and 7.1±2.4 hours in group B (Table 1 ). There were no significant differences in baseline characteristics between groups A and B (Table 1) or between treatment arms. The intervention arms did not differ from one another in prevalence of subtotal obstruction of the infarct artery, collateral flow to the infarct area, or in duration of intracoronary infusion (85.3 ±24.5 minutes). The total dose of streptokinase in the two streptokinase arms was 173,000±53,000 IU. Baseline Angiography Preintervention angiograms were available in 272 of 292 intervention patients; in 20 patients who were evenly distributed between intervention arms, angiographic data were not available primarily due to death or profound hemodynamic instability before completion of the baseline study. Of those patients with preintervention angiograms, 55 were in group A and 217 were in group B. In 268 of these patients, the time interval between onset of infarct pain and interventional angiography could be determined.
Initial Subtotal Obstruction
The prevalence of initial subtotal obstruction of the infarct-related artery was 27% (73/272). It was not related to duration of infarct pain before presentation by prospective stratification (group A, 31%, 17 of 55; group B, 26%, 56 of 217) or by time to angiography (Table 2) ; patients studied within 6 hours had a subtotal lesion in 30% (40 of 135) of the 
Delayed Appearance and Disappearance of Collaterals
The evolution of angiographically demonstrable collaterals was assessed in those 98 patients with complete obstruction at baseline angiography who either never demonstrated recanalization (n =42) or who experienced acute recanalization that was sustained at end-point angiography (n=56). In patients with persistent coronary artery occlusion, the incidence of demonstrable collaterals increased from 33% at baseline angiography to 90% at end-point study, whereas in patients with sustained reperfusion, the incidence of collaterals decreased from 38% to 7% (Figure 3 Although three of the 292 intervention patients died in the catheterization laboratory (two in the SK arm, one in the NTG arm) and none of the 101 control patients died during the corresponding observation period, there was no significant difference in mortality among the four treatment arms within the first 24 hours after randomization or through the hospital course of treatment (Table 6 ). Similarly, cardiogenic shock, which occurred in 4% of patients during interventional catheterization but not in any control patient during the observation period, was evenly distributed by study end point between intervention (10%) and control patients (9%). tA 90-minute observation period corresponding to the intervention period was considered.
During hospitalization, both anemia (p<0.01) and blood transfusion (p<0.01) were more common in intervention than in control patients (Table 7) ; however, there were no significant differences among the three intervention arms. Fibrinogen levels decreased from baseline to preintervention by 26% in patients assigned to the streptokinase arms (p<0.01), whereas there was no significant decrease in the NTG or conventional arm (Table 7) .
Intra-aortic balloon counterpulsation was used in 10% of the patients; there were no differences among the treatment arms. In keeping with the protocol of this study, the incidence of revascularization by percutaneous transluminal coronary angioplasty or coronary artery bypass surgery before end-point studies was less than 5% (19 of 393). The reinfarction rate of 4% did not differ significantly among treatment arms.
Discussion
Ttial Design
Due to the presumed time dependence of myocardial necrosis, it is common clinical practice to restrict acute angiography and interventions after the first 6 hours of pain onset to those patients who present with ongoing chest pain and electrocardiographic evidence of incomplete infarction.12,13 In the present trial, the criteria for enrollment were uniform during the first 12 hours of chest pain. Thus, the influence of the time interval from onset of infarction to interventional angiography on baseline occlusion status of the infarct-related artery, baseline collateral flow, and recanalization rates with intracoronary streptokinase could be determined prospectively.
Performance of serial angiography before intracoronary drug infusion, during intervention, immediately after intervention, and 10-14 days later in patients with acute myocardial infarction who were randomly assigned to an intracoronary infusion of streptokinase, nitroglycerin, or both drugs enabled us to compare acute as well as delayed recanalization rates in the presence and absence of thrombolytic therapy. Furthermore, we assessed the appearance and disappearance of collateral flow to the infarct area from baseline to day 10-14 in patients with permanent total coronary occlusion and in those who experienced sustained recanalization.
Finally, we designed this trial to assess complication rates of interventional catheterization in the acute stage of myocardial infarction with and without intracoronary thrombolysis. This was achieved by including a control group in which acute cardiac catheterization was not performed and an intervention group that did not receive thrombolytic therapy.
Spontaneous Recanalization
In the present trial, the prevalence of subtotal obstruction of the infarct artery did not increase with the time interval between onset of pain and baseline angiography. This result confirms, in a larger patient population, a finding of our first trial6 and contradicts the data of DeWood et al,14 who reported a significant increase in patency rates in patients studied more than 6 hours after pain onset. In contrast to our study, his results were obtained from a database gathered retrospectively and thus more likely to be subject to selection bias. Our data refute the hypothesis that there is a high incidence of spontaneous recanalization between 6 and 12 hours or, for that matter, between 3 and 14 hours after onset of infarction. Spontaneous recanalization, however, appears to occur frequently either earlier, that is, within 3 hours, or "delayed," that is, more than 14 hours after symptom onset. Early spontaneous recanalization is the most likely explanation of subtotal occlusion of the infarct artery at baseline angiography, which we observed in 27% of our patients. This hypothesis is supported by the significant ejection fraction improvement that has been found consistently in this subgroup of patients. 6, 9, 12, 15 This early spontaneous recanalization is probably due to relief of coronary spasm,3 endogenous lysis of a platelet thrombus, or both.2 Delayed spontaneous recanalization that occurred after the acute intervention and before end-point study was documented angiographically in about half of the patients treated with intracoronary nitroglycerin and systemic anticoagulants and was probably unrelated to the nitroglycerin because the end-point patency was identical in the control arm. Therefore, delayed spontaneous recanalization involves the time-consuming process of lysis of an established fibrin thrombus by the intrinsic fibrinolytic system. 
Evolution of Collateral Flow
Appearance and disappearance of collateral flow have been found to be related to interruption and restoration of antegrade flow in previous human studies using bypass surgery22 and angioplasty as models. 23 The present study allows a further analysis of the incidence and time course of the development of collateral flow in patients with thrombotic coronary occlusion.
We observed no increase in the prevalence of angiographically apparent collateral flow with timeto-baseline angiography. Therefore, it is unlikely that these collateral channels developed in response to the current total occlusion. This conclusion is supported by the experimental observation that the first cellular mitoses occur only 24 hours after coronary obstruction.24 The data support the hypothesis that the collateral channels that were visible at baseline angiography had developed in response to an antecedent high-grade coronary artery obstruction and were recruited when antegrade flow ceased. 23 The increase in the incidence of collaterals from 33% at baseline to 90% at end-point angiography in those patients in whom the infarct artery remained obstructed indicates that growth of collateral channels occurs nearly uniformly in humans within 10 days of sustained coronary occlusion.
Complications and Mortality
We observed a significant increase of lifethreatening complications during interventional catheterization as compared with the corresponding observation period in the control group. However, the lack of an increase in mortality at 24 hours or at hospital discharge in the intervention arms indicates that these complications could be managed successfully. The increase of both morbidity and mortality reported by several authors with the use of acute angioplasty may be related to the greater technical complexity of these interventions.25 26 The observed decrease of fibrinogen levels in the streptokinase arms was significant albeit less marked than in other studies27; this may be related to differences in the streptokinase dose and in the methods used to assess fibrinogen levels. The incidence of bleeding complications in the streptokinase arms of our study is in accord with other studies in which acute catheterization was combined with intracoronary streptokinase infusion27 or intravenous recombinant tissue-type plasminogen activator therapy.17 Because bleeding complications occurred with equal frequency in the NTG arm, where no decrease of fibrinogen was seen, it appears that the principal cause of bleeding in patients subjected to acute interventional catheterization is the combination of an arterial injury with prolonged systemic anticoagulation. Primary angioplasty has been advocated as an alternative to thrombolytic therapy to achieve coronary artery recanalization with a low risk of bleeding. However, the risk of thrombotic reocclusion necessitates prolonged heparinization after primary angioplasty. This therapeutic modality, therefore, will probably be associated with an incidence of hemorrhagic complications comparable with that incidence found in our 
